Miromatrix Medical Inc

Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. It offers perfusion decellularization and recellularization technology, as well as organ-derived biological products such as MIROMESH and MIRODERM for soft tissue reinforcement and advanced wound care. The company was founded in 2009 by Doris A. Taylor and Cohen Robert and is headquartered in Eden Prairie, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Miromatrix Medical is a biotechnology company engaged in the development of fully biological human organs and organ-derived biological products to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization or recellularization technology, as well as organ-derived biological products for applications such as soft tissue reinforcement and advanced wound care.  It was founded in 2009 and is based in Eden Prairie, Minnesota.

United Therapeutics

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per.

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“Merger Sub”), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon th.

United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a.

MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO

MILWAUKEE , Oct. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Miromatrix (Nasdaq: MIRO) for possible breaches of fiduciary duty and other violations of law in its transaction with United Therapeutics. Click here to learn how to join the action https://www.ademilaw.com/case/Miromatrix-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Miromatrix Medical Inc. has obtained a Fair Price in its transaction with United Therapeutics

Shares in the artificial human organs specialist Miromatrix Medical Inc. jumped 25% in premarket trading following the announcement of its acquisition by United Therapeutics Corporation (NASDAQ:UTHR) for up to $140 million.

Miromatrix Medical climbs 225% following $140m United Therapeutics bid

Miromatrix Medical (NASDAQ: MIRO ) stock is rocketing higher on Monday after announcing an acquisition deal with United Therapeutics (NASDAQ: UTHR ). That deal has United Therapeutics agreeing to acquire Miromatrix Medical for $91 million in cash, which comes to $3.25 per share.

Why Is Miromatrix Medical (MIRO) Stock Up 235% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Miromatrix Medical Inc. (NASDAQ: MIRO) to United Therapeutics Corporation is fair to Miromatrix shareholders. Under the terms of the proposed transaction, United Therapeutics would acquire all outstanding shares of Miromatrix for $3.25 per share in cash and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's kidney prod.

MIRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Miromatrix Medical Inc. Is Fair to Shareholders

Miromatrix Medical Inc.'s stock MIRO, -2.80% jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. UTHR, -2.30% for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix's development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025.

Miromatrix Medical stock soars after it agrees to be bought by United Therapeutics

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix.

United Therapeutics to Acquire Miromatrix Medical.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare, life-threatening condit.

United Therapeutics to Acquire Miromatrix Medical

EDEN PRAIRIE, Minn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement ("ISODP") Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort.

Miromatrix to Present at the 2023 ISODP Organ Donation Congress

EDEN PRAIRIE, Minn., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA. The three-day event, held this year on October 10-12, will feature presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa

EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the H.C. Wainwright Annual Global Investment Conference on September 11th, 2023.

Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference

EDEN PRAIRIE, Minn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming Alliance for Regenerative Medicine (ARM) Tissue Engineering and Therapeutics Workshop held on September 6, 2023.

Miromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshop

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Max Forgan - Gilmartin Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Phillip Dantoin - Piper Sandler Operator Good day, and welcome to the Miromatrix Medical, Inc. Second Quarter 2023 Earnings Conference Call. All participants' will be in listen-only mode.

Miromatrix Medical Inc. (MIRO) Q2 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update.

Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Second Quarter 2023 Financial Results

EDEN PRAIRIE, Minn., July 13, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that its poster entitled Initial Preclinical Evaluation of a Bioengineered Kidney was selected Best in Congress at the recent American Transplant Congress (ATC).

Miromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement Award

EDEN PRAIRIE, Minn., June 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that Miromatrix and John Barry have mutually agreed to end his employment as Vice President of Research and Development ("R&D") effective on or around June 13, 2023, and that Jeff Ross, Ph.D., Chief Executive Officer, will assume leadership responsibilities for the R&D organization.

Miromatrix Announces CEO Jeff Ross, Ph.D. will Expand His Role by Resuming Leadership of R&D

EDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced it will be presenting at the upcoming 2023 American Transplant Congress ("ATC") held on June 3rd to June 7th, 2023 in San Diego, California.

Miromatrix Presenting at the 2023 American Transplant Congress

EDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management team will participate in the upcoming 20th Annual Craig-Hallum Institutional Investor Conference on May 31st, 2023. Due to the format of this event, no webcast will be available.

Miromatrix Announces Participation in the 20th Annual Craig-Hallum Institutional Investor Conference

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Hannah Jeffrey - Gilmartin, Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Operator Greetings and welcome to the Miromatrix Medical, Inc. First Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Miromatrix Medical Inc. (MIRO) Q1 2023 Earnings Call Transcript

Miromatrix Medical Inc. (MIRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago.

Miromatrix Medical Inc. (MIRO) Reports Q1 Loss, Misses Revenue Estimates

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2023 financial results and provided a corporate update.

Miromatrix Reports First Quarter 2023 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

News for Miromatrix Medical Inc Stock (MIRO)